The approval was based on data from the phase 3 CARTITUDE-4 study. The FDA has approved Carvykti for the treatment of adults with relapsed or refractory multiple myeloma after at least 1 prior lines of therapy.
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Johnson & Johnson: CARVYKTI is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) Contineum Therapeutics, Inc. (Contineum), a clinical stage biopharmaceutical company focused on discovering.
SAN DIEGO, April 04, 2024 Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target.